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Available online 27 February 2017Cardiovascular disease is a leading cause of death in women, nevertheless it is often underestimated in female
patients without overt risk factors. The chronic infection by Human Immunodeﬁciency Virus (HIV) is clearly as-
sociated, along with the use of certain antiretroviral drugs and traditional risk factors, with an increased risk of
cardiovascular diseases. The aim of this manuscript is to review the epidemiology, risk factors, pathogenesis, di-
agnostic approach, primary and secondary prevention strategies of cardiovascular disease in HIV-negative and
HIV-positive female subjects. The ultimate goal is to promote knowledge and development of speciﬁc and appro-
priate clinical interventions and guidelines in this group of high-risk patients, mostly in view of the expected
growth of ageing females with HIV.
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Cardiovascular prevention1. Introduction
Cardiovascular disease (CVD) accounts for N17 million deaths glob-
ally each year, which represent approximately 30% of all deaths. Of note
80% of CVD occurs in low- andmiddle-income countries [1]. CVD is also
the leading cause of death in women and it is often underestimated
owing to a general misperception that females are less susceptible and
have a lower CV risk. Notably it is estimated that 50% of American
women will die of coronary heart disease (CHD) or stroke, compared
to 1 in 25 of breast cancer [2]. Females have lower risk for CVD and spe-
ciﬁcally acute myocardial infarction (AMI), compared to males (−22%
after adjusting for several risk factors) [3]. Sex-related features, such
as smaller body size andweight, slower drugmetabolism and decreased
renal function, as well as co morbidities and concomitant drug therapy,
may speciﬁcally inﬂuence incidence and outcomes of CVD. Among co-
morbidities,whichmayheavily affect CV risk inwomen,much attention
has been recently developedwith regards to human immunodeﬁciency
virus (HIV) and antiretroviral therapy in HIV.Molecular Medicine, School of
za University of Rome, Via di
e).
eliability and freedom from bias
land Ltd. This is an open access articlIn fact, HIV-positive patients have a higher risk of CV disorders be-
cause of several HIV- and non-HIV-related features. With the increased
life expectancy associated with highly active antiretroviral therapy
(HAART) non-acquired immunodeﬁciency syndrome (AIDS) CV com-
plications are therefore now recognized as a leading cause of death in
this population [4]. In particular, several studies have analysed large
clinical databases and cohorts worldwide to compare the incidence of
CVD in patients with and without HIV infection. These studies consis-
tently report a 1.5-fold increase in the rate of CV events in HIV-
infected individuals compared to controls [5,6]. The incidence of CHD
in the years 1994–2000 was low overall, but higher in those infected
with HIV compared with the uninfected, even in the younger strata
[7]. Although most of the studies in HIV-positive patients have been
conducted in male subjects, HIV infection has been associated with a
signiﬁcant risk of CVD in females [8,9]. In two studies, the age-
adjusted relative risk of AMI was found to be higher in female than
male subjects as compared to HIV-negative patients; risk ratios were
2.98 (USA) and 2.7 (France) for females and 1.40 (USA and France) for
males [10,11]. In a recent study conducted in United States female vet-
erans incident CVD/1000 person-years was signiﬁcantly higher among
HIV-positive than HIV-negative women with a hazard ratio of 2.8 after
adjusting for CV risk factors [12].
In view of the commonly less aggressive clinical approach (including
prevention and stringent diagnostic screening) adopted in women, thee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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represent a clinically emerging issue in the ageing HIV population.
2. HIV and increased risk of CVD
Despite HIV-positive patients have been recognized at signiﬁcant
higher risk of CVD, there is still uncertainty on the relative role that
has to be attributed to HIV, to antiretroviral treatment or to concur-
rent major CV risk factors [13]. Early studies reported a higher prev-
alence of hypertension (21.2% vs.15.9%), diabetes (11.5% vs. 6.6%)
and dyslipidaemia (23.3% vs. 17.6%) in HIV-infected patients com-
pared to the non-HIV subjects (p b 0.0001 for each comparison)
[14–15]. Smoking habit, illicit drug use and heavy alcohol consump-
tion have been reported to bemore common in HIV-positive subjects
and these bad habits may inﬂuence CVD presentation and treatment
[16–17]. Chronic renal disease is not uncommon in HIV-positive
treated subjects due to the effect of the virus and to the nephrotoxic
consequences of several antiretrovirals [18].
Speciﬁc factors that may expose HIV-positive patients to higher CVD
susceptibility might also be linked to immune-depression and HAART
treatment. Theevidence for a potential role of CD4 lymphocyte depletion
and immune activation in the development of CVD among individuals
with HIV infection is still debated [19,20]. Changes in body fat distribu-
tion (lipodystrophy including both lipoatrophy and lipohypertrophy)
are not uncommon in HIV-infected subjects: this abnormal fat redistri-
bution has clear clinical implications, such as modiﬁcations of body
reshaping and self-perception (thus affecting compliance and self-
commitment, medication adherence and mood), ectopic fat distribution
(mostly in heart, liver andmuscle tissues) and, eventually, increased CV
risk [21].
“Old” nucleoside reverse transcriptase inhibitors (NRTIs, such as zi-
dovudine, didanosine and stavudine) and protease inhibitors (PI, such
as indinavir and lopinavir/ritonavir) are associated with increased
total and low density lipoprotein (LDL)-cholesterol and lipodistrophy
thus increasing CV risk. Additional drug-associated effects include re-
duced insulin sensitivity, endothelial dysfunction and cardiac remodel-
ling [22]. An increased CV risk has been observed with indinavir and
lopinavir/ritonavir in a large cohort study [23]. Abacavir, a widely used
NRTI, has been associated to a higher risk of CVD although data appear
controversial: independent cohort studies conﬁrmed such potential as-
sociation of recent abacavir use with CVD, but the underlying biological
mechanisms are still uncertain [24,25].
The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D)
study has recently updated the prediction model for CVD using data
from32,663HIV-positive individuals [26]. The full D:A:DCVDprediction
model includes exposure to antiretroviral drugs (cumulative protease
inhibitor and NRTI exposure, current abacavir use) and markers of im-
munodeﬁciency (CD4 lymphocyte count), in addition to modiﬁable
and non modiﬁable CV risk factors [age, gender, family history of CVD,
systolic blood pressure (SBP) and smoking status, total and high density
lipoprotein (HDL) cholesterol, diabetes]. The performance of themodels
was superior to that of a recalibrated Framingham CVD prediction
model in this population. In a large cohort of 11,338 HIV-positive pa-
tients several risk scores [Framingham, Adult Treatment Panel-3 (ATP-
3), Atherosclerotic Cardiovascular Disease (ASCVD) and D:A:D] were
compared as for their ability to predict incident type 1 (spontaneous
fromatherosclerotic plaque instability) and type 2 (secondary to oxygen
demand/supply mismatch) AMI. ASCVD displayed a signiﬁcantly better
area under the curve (AUC) than other scores for all AMIs and for type 2
AMIs, and was not inferior to the other AUCs for type 1 AMIs [27].
3. CVD risk in HIV-positive women
HIV-positive women present CV risk factor proﬁles substantially
comparable to those discussed of HIV-positivemale individuals. Gender
differences such as lower body weight, slower drug metabolism andhormonal control of intranuclear receptors may explain differences in
drug exposure as well as a higher prevalence of antiretroviral-
associated toxicities [28]. Furthermore the use of CVD-related therapeu-
tic interventions (with the exclusion of anti-hypertensive drugs) is
lower in HIV-positive female as compared tomale subjects with similar
risk proﬁles [29]. The prevalence of early and premature (b40 years of
age) menopausewas deemed to be variable, but higher than usually re-
ported in HIV-negative subjects (20–27% versus 5% early and 2–5% ver-
sus b1% premature menopause). Several demographic, nutritional,
lifestyle and clinical factors (including HCV co-infection and severe
immune-depression) have been associated with early menopause in
HIV-positive patients [30,31].
The potential relationship between speciﬁc CV risk factors and de-
velopment of tailored interventions has been poorly explored in HIV-
positive females: studies assessing the role of early menopause as well
as of hormonal therapies are needed in order to evaluate possible im-
provements in womens' care.
4. Pathogenetic considerations
The relative contribution of various pathogenic processes leading to
AMI differs markedly between genders. Patients with evidence of AMI
and non-obstructive atherosclerotic disease of the coronary arteries
are more likely to be women and non-white [32]. Other mechanisms
may play a role in women, such as abnormal coronary vasomotion,
non-atherosclerotic coronary artery dissection, impaired coronary mi-
crocirculation and thrombophilia.
On the other hand, HIV-positive patients have an increased risk of
subclinical atherosclerosis [33]. A recent meta-analysis reported that
HIV-infected patients present higher rates of non-calciﬁed plaques
(NCP) compared to similar cohorts of HIV-negative subjects and that
NCP prevalence and degree were positively associated with worse
immune-virological parameters, suggesting that the disease stage con-
tributes to development of coronary plaque instability [34,35]. NCPs
represent an early stage of atherosclerosis, resulting to be more prone
to rupture and thrombus formation compared to calciﬁed lesions, po-
tentially predisposing to AMI, as observed in several case series of
HIV-positive patients.
HIV infection leads to disarray of immune systemand persistent sys-
temic immune hyper activation in spite of full HIV viremia suppression
by antiretroviral treatment. In particular, soluble CD14 (sCD14) and sol-
uble CD163 (sCD163), both known markers of monocyte/macrophage
activation, have been identiﬁed as reliable predictors of increased ath-
erosclerotic disease as detected by coronary computed tomography
(CT). Moreover, CD14 has been associated with an increased risk of
death in HIV-positive patients and a history of heart disease [36]. Fur-
thermore, higher levels of inﬂammatorymarkers, (high-sensitivity c re-
active protein, interleukin 6) and coagulation markers such as D-dimer,
have been reported in HIV-infected patients and are associated with
fatal and non-fatal CV events and all-causemortality in HIV-positive pa-
tients [37].
Interestingly, microbial translocation has been proposed as a main
mechanism behind immune hyperactivation during HIV infection [38].
Most recently, microbiota-derived metabolites of phosphatidilcoline,
more speciﬁcally trimethylamine and oxidized-TMA were associated
with coronary plaque burden at CT in HIV-positive patients, thus sug-
gesting that diet and intestinal microbiota may signiﬁcantly impact ac-
celerated atherosclerosis in HIV-infected patients.
Limited data are available so far about pathogenetic determinants of
atherosclerosis in HIV-positive women. In young and asymptomatic
HIV-positive women with many risk factors (cigarette smoking, diabe-
tes, obesity and illicit drug abuse) signiﬁcantly higher percentages of
segments with NCP (74% vs. 23%) were found, compared to HIV-
negative controls. CT scan also showed more segments with NCP (0.92
vs. 0.40). Immune activation parameters, including sCD163, CXCL10
and CD14+, CD16+ monocytes were higher in HIV-infected than
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women with NCP compared to those with calciﬁed plaques, thus
supporting the inﬂammatory nature of NCPs [39].
Several gaps exist in our knowledge of CVD pathogenesis in HIV-
infected women: longitudinal studies assessing the formation and fea-
tures of plaques, the role of antiretroviral treatment and levels of im-
mune activation and accelerated senescence are needed in order to
design speciﬁc primary and secondary interventions.
5. Diagnostic approach
For the diagnosis of CHD in female subjects, the use of imaging tests
is recommended because of the relatively lowpredictive value of the ex-
ercise tolerance test (ETT), widely used and more reliable in man [40].
Indeed, HIV-positive patients, having a high pre-test probability of
CHD, may further beneﬁt from imaging techniques with the screening
program. On the other hand, women are generally less likely to receive
cardiac imaging than men to diagnose or rule out ischemic heart dis-
ease. The reasons behind this gender difference are unclear [40], though
theymight be related to a persistentmisperception of the risk of CHD in
women still today.
Myocardial perfusion scintigraphy has been used to assess the prev-
alence of perfusion defects in HIV-positive and matched negative sub-
jects without known CV risk factors: HIV patients demonstrated
higher prevalence of perfusion defects than controls (18% vs. 0%;
p b 0.001) [41]. Using cardiac magnetic resonance imaging (MRI),
HIV-infected adults showed reduced myocardial function as compared
to controls in the absence of known CVD. This is associated with evi-
dence abnormal myocardial tissue composition, characterized by in-
creased lipid component and diffuse myocardial ﬁbrosis and raised
inﬂammatory markers [42].
The risk–beneﬁt ratio between using a test that requires ionizing ra-
diation (i.e. CT), which has shown to be effective in rule out CHD and
predict CV prognosis in both sexes, compared to one that does not re-
quire radiation, remains unclear in women [43].
Recent evidence is also shifting the focus of imaging from an
anatomy-based CHD diagnosis to a more functionally-based test. This
is because women are more likely thanmen to suffer frommicrovascu-
lar cardiac disease, speciﬁcally at the level of the precapillary coronary
arterioles [40].
Today, because of the lack of evidence, the exact diagnostic approach
for subclinical atherosclerotic disease in HIV-positive women remains
uncertain: whereas coronary CT scan might be reserved to selected
high-risk cases, the ultrasound evaluation of carotid plaques might be
useful in the attempt to correctly classify patients with intermediate
CV risk. The widest experience derives from the use of carotid ultra-
sound in HIV-positive patients: the prevalence of plaques is higher in
HIV-positive patients and the progression is more rapid [44].
6. Primary prevention
Recent guidelines have approached the most appropriate primary
prevention strategy in HIV-negative female patients [45]. In HIV-
positive patients, recommendations for the prevention of CVD have
been included in the European AIDS Clinical Society (EACS) guidelines
as well as in the Italian guidelines for the use of antiretroviral agents
and the diagnostic-clinical management of HIV-1 infected persons [46,
47]. So far, no speciﬁc recommendations have been issued for HIV-
positive women. Annual estimation of patients' CV risk in those aged
above 40 (male) or above 50 (female) years using either the Framing-
ham equation or American College of Cardiology/American Heart Asso-
ciation (ACC/AHA) ASCVD risk calculator or the previously mentioned
D:A:D risk calculator, which include data about lopinavir and abacavir
assumption, are currently recommended. ACC/AHA ASCVD risk calcula-
tor, which gives an estimation of major CV events in the lifetime, seems
to be more reliable in HIV patients [48].Based on the EACS guidelines and considering the recommendation
from the Italian Ministry of Health for the management of HIV female
patients, Fig. 1 proposes an algorithm for the screening of CV risk in
HIV- positive women.
Actually, in this regard, the possibility that the risk score for ASCVD
from ACC/AHA might underestimate the risk of AMI in speciﬁc groups
of subjects has been recently challenged by Feinstein et coll. (49) Indeed,
it is unknown how well the ACC/AHA pooled cohort equations—based
on risk factors of sex, race/ethnicity, total cholesterol, HDL-cholesterol,
smoking, diabetes, SBP, and antihypertensive treatment—predict
ASCVD risk in blackmen andwomen and inwhite women. To better ad-
dress this issue, especially in women, Feinstein et coll. Proposed two
HIV-speciﬁc MI risk estimation models including variables from the
ASCVD risk score plus statin use and HIV-speciﬁc variables, such as
HIV viral load, CD4 lymphocyte count, antiretroviral therapy, and
protease-inhibitor use. Actually, in contrast with proponents' expecta-
tions, in a large, multicenter HIV positive cohort, the two new risk-
estimation models did not discriminate MI risk any better than the
ACC/AHA pooled cohort equation [49].
Proposed interventions in HIV positive female subjects focus on 4
key modiﬁable risk factors beside lifestyle changes: smoking cessation,
control of BP, reduction of glucose levels (if diabetics) with the target
of HbA1C b6.5–7%, control of lipid abnormalities with drug therapies
(if 10-year CVD risk ≥10%or diabetics)with standard and optimal target
for total cholesterol (190 and 155mg/dL) and LDL-cholesterol (115 and
80mg/dL, respectively). The guidelines also suggest low-dose aspirin in
patients above 50 years of agewith 10-year estimated CVD risk N20%. In
the setting of HIV infection low dose aspirin is underused, though itmay
hold potential advantages that need to be investigated in larger pro-
spective trials [50].
Moreover, besides suggesting ﬁrm lifestyle interventions in all pa-
tients, it has been proposed to consider HAART changes if 10-year calcu-
lated CVD risk exceeds 20%. Although several treatments, thoroughly
discussed in the Italian guidelines, have been associated with better
lipid proﬁle, reduced platelet hyper-reactivity and increased insulin
sensitivity, the impact of switching to such drugs on the prevention of
CV events is unclear [51]. Furthermore several clinically relevant drug-
to-drug interactions must be considered when co-administering CV
drugs and HAART (Table 1) [52].
Primary preventionwill be a key feature of integrated care of people
living and ageing with HIV: evidence-based interventions considering
both pharmacological and non-pharmacological interventions must be
prospectively assessed and cost–beneﬁt established.
To further investigate the role of statins in decreasing CVD risk in
HIV–infected individuals, a clinical trial funded by the National Insti-
tutes of Health (REPRIEVE) began in 2015 [53].
7. Secondary prevention
Although much research on gender difference has been performed
during the acute phase of CHD, little is still known about sex disparity
in the secondary prevention setting.
It has been previously reported that women after an ACS are less
likely to achieve LDL-C target levels, BP control and fasting glucose nor-
mal values [54]. This is apparently the consequence of under usage of
preventive strategies in female subjects. In particular, there is a reduced
use of lipid-lowering therapy between men and women with CHD,
since they tent to receive insufﬁcient doses of statins and combination
lipid-lowering therapy and are less likely than men to achieve their op-
timal LDL and HDL cholesterol goals [55]. On the contrary, clinical stud-
ies indicate that both genders, when appropriately treated, have similar
improvements in CV risk factor [56].
Speciﬁc guidelines for secondary prevention in HIV-positive male
and female subjects have not been produced. In view of the higher
risk of subsequent CV events in patients who already suffered from
AMI or revascularization, it seems reasonable at this time to apply the
Fig. 1. Suggested clinical approach for periodical CV risk estimation and management. (i) ACC/AHA ASCVD risk calculator should be preferred (http://tools.cardiosource.org/ASCVD-Risk-
Estimator/). This assessment and the associated considerations outlined in this ﬁgure should be repeated annually in all persons under care to ensure that the various interventions are
initiated in a timely way.CAC: coronary artery calcium; IMT: intima-media thickness; ABI: ankle brachial index; SBP: sistolic blood pressure; DBP: diastolic blood pressure; TC: total
cholesterol; HDL-C: high density lipoprotein cholesterol; LDL- C: low density lipoprotein cholesterol; TG: triglycerides; DM: diabetes mellitus; CVD: cardiovascular disease; HAART:
highly active antiretroviral therapy; TOD: target organ damage.Figure modiﬁed from reference [45,46].
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sued for the general population [57].
Some speciﬁc issues, however, need to be considered. The spectrum
of CHD in HIV-infected patients is similar to that in non–HIV-infected
patients and the extension of coronary involvement is generally low,
being more frequent the report of single-vessel disease [58]. The
short-term outcomes of both percutaneous coronary intervention
(PCI) and coronary artery bypass grafting (CABG) seem to be similar
inHIV-positive andHIV-negative patients. However, in HIV-infected pa-
tients a higher rate of recurrent ischemic events was reported [59]. In
the PACS (Prognosis of Acute Coronary Syndrome in HIV-Infected Pa-
tients) study, recurrent ACS was more frequent in HIV-infected com-
pared to uninfected patients [16]. A meta-analysis of studies
conducted on PCI showed that HIV-infected patients with ACS had a sig-
niﬁcantly higher long-term risk for recurrent coronary revascularization
and MI and it has been suggested that drug- eluting stents might be a
better option in HIV-positive patients [60,61]. Another multicenter
study suggests that HIV-positive patients may undergo less-invasive
strategies and are discharged less frequently on dual antiplatelet thera-
py (53% versus 88%, in HIV negative) and statins (64% versus 89%) [62].
Furthermore, occurrence of sudden cardiac death in HIV-positive pa-
tients was found 4.5-fold higher than expected (2.6 per 1000 person-
years, 95%CI 1.8–3.8). This could be related to myocardial ischemia, ar-
rhythmias or other abnormalities in these patients [63]. The underutili-
zation of aspirin in HIV-positive subjects has also been reported in
secondary prevention strategies, probably reﬂecting a concern of
major bleeding in these “fragile” subjects. Recent data suggest a lower
response to aspirin inHIV-positive subjects [64]. Simultaneously theun-
derutilization of dual antiplatelet therapy and high-dose statins may be
accounted for by a reasonable concern of signiﬁcant drug/drug interac-
tions (DDIs). Indeed, cohort studies reported that CV and antiretroviral
drugs are the most common compounds to generating clinically rele-
vant DDIs. Speciﬁc reviews and updated websites (http://www.hiv-
druginteractions.org) may help to get a better appraisal for the optimi-
zation and safer management of complex pharmacological regimens in
HIV patients [65].
8. Other HIV-CV related diseases
Individuals with HIV are exposed to many pathologic modiﬁcations
and the ﬁnal clinical expression of CVDs is highly variable and dependson a number of factors, such as the stage of the HIV infection and subse-
quent degree of immunodeﬁciency, combination with HAART, associat-
ed opportunistic infections, drug interactions and toxicities.
The high risk of secondary CV events and associated mortality sup-
ports the need for immediate, aggressive and collaborative efforts (in-
cluding infectious disease specialists, cardiologists and nutritionists)
aiming at a signiﬁcant reduction of risk. The appropriate interventions
are yet to be deﬁned in both HIV-positive male and female subjects.
Among these, HIV-related cardiomyopathy may present as 1) focal
myocarditis; 2) subclinical left ventricular (LV) or right ventricular dys-
function and 3) symptomatic dilated cardiomyopathy with reduced
ejection fraction [66]. The reported prevalence rates for HIV associated
cardiomyopathy vary widely due to nonuniform deﬁnitions, different
approach to diagnosis, and studies in different populations. Moreover,
it is often subclinical, therefore itmay go undetected [67]. An Italianpro-
spective echocardiographic study in 114 HIV-positive patients found
that the prevalence of cardiomyopathy in AIDS patients was 16.6%
[68]. A recent meta-analysis of studies evaluating cardiac dysfunction
during HIV infection in the context of HAART therapy identiﬁed LV sys-
tolic dysfunction in 8% and diastolic dysfunction in as many as 43% of
HIV-infected adults [69].
Several mechanisms for the pathogenesis of HIV associated cardio-
myopathy have been proposed from the direct HIV cardiac myocyte in-
vasion to the promotion of abnormal detrimental inﬂammatory
response in situ leading to abnormal myocardial tissue composition
characterized by increased lipid components and diffuse myocardial ﬁ-
brosis [42,70]. Despite the lack of data that HAART can reverse HIV-
associated cardiomyopathy, HAART should be instituted in all patients,
as restoration of immune status and suppression of the virus may ame-
liorate cardiac dysfunction [71].
HIV infected patients have a greater incidence of pulmonary artery
hypertension (PAH) compared to general population [72]. It was esti-
mated to occur in 0.5% of HIV-positive patients in the pre-HAART age,
and, interestingly, its prevalence has not changed, despite the introduc-
tion of HAART [73]. Indeed, since HAART has substantially improved the
survival rates of patients with HIV, chronic cardiac conditions, such as
PAH, are signiﬁcantly increasing [74]. Reports about HIV positive sub-
jects in African showed that there is no difference between the preva-
lence in male (6–19%) and in female people (around 10%) [75]. On the
other hand, a study including N800 people from the urban population
in one of the largest industrial areas in the middle of Europe showed
Table 1
Drug–drug interactions with compounds used for treating cardiovascular disorders.
Drug or drug class NRTIs NNRTIs bPIs INSTI CCR5I
NRTIs EFV NVP ETV RPV LPV ATV DRV RAL bEVG DGV MVC
Anti-hypertensive drugs ACE inhibitors OK OK OK OK OK OK OK OK OK OK OK OK
Sartans OK OK OK OK OK OK OK OK OK OK OK OK
Beta-blockers OK OK OK OK OK OK OK OK OK OK OK OK
Calcium-antagonists OK Titer dose Titer dose Titer dose Titer dose Titer dose Titer dose Titer dose OK Titer dose OK OK
Furosemide OK OK OK OK OK OK OK OK OK OK OK OK
Thiazide diuretics OK OK OK OK OK OK OK OK OK OK OK OK
Anti-coagulants and anti-platelets drugs Warfarin OK Titer dose Titer dose Titer dose Titer dose Titer dose Titer dose Titer dose OK Titer dose OK OK
Clopidogrel OK Caution–alt? Caution–alt? Caution–alt? Caution–alt? Caution–alt? Caution–alt? Caution–alt? OK Caution–alt? OK OK
Apixaban OK Caution–alt? Caution–alt? Caution–alt? Caution–alt? No No No OK No OK OK
Rivaroxaban OK Caution–alt? Caution–alt? Caution–alt? Caution–alt? No No No OK No OK OK
Dabigatran OK OK OK OK OK ? Caution ? Caution ? Caution OK ? Caution OK OK
Aspirin OK OK OK OK OK OK OK OK OK OK OK OK
Heparins OK OK OK OK OK OK OK OK OK OK OK OK
Anti-arrhytmics and dopamine Amiodarone OK OK OK OK OK No No No OK No OK OK
Flecainide OK OK OK ? OK No No No OK No OK OK
Lidocaina OK ? ? ? OK No No No OK No OK OK
Propaphenon OK ? ? ? OK No No No OK No OK OK
Dopamine OK OK OK OK OK OK OK OK OK OK OK OK
Cardiac failure, pulmonary hypertension Digoxin OK OK OK OK OK Titer dose Titer dose Titer dose OK Titer dose OK OK
Doxazosin OK OK OK OK OK OK OK OK OK OK OK OK
Nitrates OK OK OK OK OK OK OK OK OK OK OK OK
Bosentan OK OK OK OK OK Titer dose Titer dose Titer dose OK Titer dose OK MVC dose
Sildenaﬁl OK OK OK OK OK Titer dose Titer dose Titer dose OK Titer dose OK OK
Lipid-lowering Atorvastatin OK OK OK OK OK Titer dose Titer dose Titer dose OK Titer dose OK OK
Fluvastatin OK Titer dose OK Titer dose OK OK OK OK OK OK OK OK
Pravastatin OK Titer dose OK OK OK OK OK No OK OK OK OK
Rosuvastatin OK OK OK OK OK Titer dose Titer dose Titer dose OK OK OK OK
Simvastatin OK OK OK OK OK No No No OK No OK OK
Fibrates OK OK OK OK OK OK OK OK OK OK OK OK
Ezetimibe OK OK OK OK OK OK OK OK OK OK OK OK
NRTI, Nucleoside reverse transcriptase inhibitors; NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitors; PIs, Protease inhibitors; INSTI, integrase strand transfer inhibitor; CCR5I, C-C chemokine receptor type 5 Inhibitor; EFV, Efavirenz; NVP, Ne-
virapine; RVP, Aspartyl Protease; LPV, Lopinavir; ATV, Atazanavir; DRV, Darunavir; RAL, Raltegravir; bEVG, Elvitegravir; DGV, Dolutegravir; MVC, Maraviroc; ACE, angiotensin converting enzyme.
Filled with data from http://www.hiv-druginteractions.org. (Last accessed February 15th, 2016).
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marked female predominance in symptomatic HIV–PAH [74]. The pres-
ence of PAH is of crucial importance since about two-thirds of thedeaths
in patients with HIV-related PAH are due to its consequences, such as
right heart failure, cardiogenic shock and sudden death [76].
The pathophysiology of HIV-PAH is still questioned. The absence of
viral particles in vascular pulmonary lesions suggests an indirect action
of the virus, with abnormal inﬂammation process acting as a trigger in
predisposed individuals [77]. The effect of HAART on patients with
HIV-PAH is controversial [74] and it is also important to be aware of po-
tential drug interactions in patients with HIV-PAH as some speciﬁc
HAARTs might modify metabolism and side effects of PAH therapies
[78].9. Conclusions
HIV-infected women have increased rates and risk of incident CVD
events, as compared to uninfected women, after adjustment for demo-
graphic characteristics, risk factors, other comorbidities, and substance
use and abusewith additional burden also linked to the use of antiretro-
viral drugs. Future studies should focus on the identiﬁcation of risk fac-
tors contributing to this excess of CV risk among HIV-infected women
and on the development of strategies based on appropriate ﬂow-
charts to prevent CVD in this high-risk population. The implementation
of the current clinical approach in women (improved diagnosis and ap-
propriate interventions in primary and secondary prevention) repre-
sents a growing important issue in the prespective of progressively
ageing HIV population. This may result in an improvement in preven-
tion of future CVD, in the quality of life of the patients and in a potential
reduction of the mounting healthcare costs related to the clinical and
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